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In an observational study in men with erectile dysfunction (ED) consulting a general practitioner
(GP) or urologist in Belgium, demographics, ED characteristics (including erection hardness score),
co-morbidities and treatment expectations were evaluated using a structured questionnaire. In total,
341 GPs and 41 urologists recruited 1492 patients. Most (74%) were untreated and 25% had ED for
43 years. Considering PDE5 inhibitors, erection hardness (89%) and maintenance (92%) were
considered ‘very important’ by most patients. Only 18% of physicians initiated discussion about ED,
despite 41% of patients havingX3 known risk factors. The questionnaire was considered helpful by
81% of GPs and 83% of their patients. Overall, patients are under-diagnosed, and physicians are
reluctant to ask about ED. A questionnaire including erection hardness score is useful to facilitate
discussion about ED in general practice. Erection hardness and maintenance are more important to
patients as compared to fast onset or long duration of action.
International Journal of Impotence Research advance online publication, 17 April 2008;
doi:10.1038/ijir.2008.7
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Introduction
Erectile dysfunction (ED) is defined as the persistent
inability to attain and/or maintain an erection
sufficient for satisfactory sexual intercourse.
Although psychological factors can contribute, ED
is often caused by organic factors, including ather-
omatous arterial disease, neurological disorders,
venous insufficiency, endocrine disorders, injury
or operations.1 Since the approval of sildenafil
in 1998, oral phosphodiesterase type 5 inhibitors
(PDE5i) have become the first-line therapy providing
effective, safe and well-tolerated treatment.2
As a result of differences in definitions and
methodologies, prevalence rates of ED vary substan-
tially across epidemiological studies. Most studies
however support the results of the Massachusetts
Male Aging Study, demonstrating an exponential
rise of ED with age.3 The prevalence of moderate to
severe ED increased from 22% in men aged 40–50
years to 49% in men aged 60–70 years. In a
population-based study in Belgian men aged 40–70
years, estimated prevalence rates were 10%
for severe ED, 25% for moderate ED and 27% for
mild ED.4
Erectile dysfunction affects the quality of life of
patients and their partners, and can be reversed by
appropriate intervention with a PDE5i.5,6 Further-
more, recent studies have emphasized the clinical
importance of the vascular pathogenesis of ED by
identifying it as an observable marker for cardiovas-
cular risk.7–9 Many patients are however reluctant to
discuss ED with their physicians, and many physi-
cians are still uncomfortable when discussing or
evaluating sexual (dys)function. A recent study
conducted in 1000 patients in Belgium confirmed
that ED is still a taboo topic.10 Although 72% of
urologists and 49% of general practitioners (GPs)
stated that they initiated communication on ED,
73% of patients claimed the opposite. As a result of
this lack of communication, physicians do not
always address patients’ expectations adequately
regarding treatment goals and differences between
oral treatment options, such as onset and duration of
action, safety, tolerability or costs. One particularly
difficult factor to address is erection hardness,
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although it is of critical importance in treatment
success.11 In a study involving 1960 men, insuffi-
cient efficacy was the main reason (83%) to switch
treatment. Moreover, patients were more satisfied
with the new treatment because it yielded stronger
erections (73%).12 One simple way of assessing
erection hardness is the four-point Erection Hard-
ness Score (EHS),11,13 and recent studies have
shown that even a shift from score 3 (penis hard
enough for penetration but not completely hard) to
score 4 (penis is completely hard and fully rigid)
correlates with statistically significant increases in
self-esteem, confidence, sexual relationship and
overall relationship (Self-Esteem and Relationship
questionnaire) as well as increases in satisfaction,
orgasmic function, sexual desire and intercourse
satisfaction (International Index of Erectile
Function, IIEF).11,14
The Stimulate Communication On Rigidity in
Erectile Dysfunction (SCORED) study was designed
to evaluate the importance of erection hardness as a
patient expectation of pharmacological treatment.
A structured questionnaire was used to
facilitate diagnosis and discussion of ED and to
systematically establish patients’ expectations about
PDE5i treatment. The profile of ED patients
in Belgium was also determined in the study.
Methods
Study design
SCORED was an observational, multicentre, non-
interventional study in Belgian men discussing ED
with their GP or urologist. Eligible patients included
men over 18 years of age who either consulted a GP
or urologist for first diagnosis of ED or were already
treated for ED. The protocol was approved by the
Ethics Committee of Flemish General Practitioners.
All patients provided written informed consent.
Data collection
A structured questionnaire, designed as a logical
guide for physicians to run through patient char-
acteristics and stimulate discussion on ED, was
used. Patients were asked to provide demographic
data and information about the consultation (age,
reason for consultation, first time discussion on ED,
presence of partner, initiation of ED discussion,
steady relationship with partner, spontaneous re-
ference to importance of rigidity of erection, treat-
ment status). The physician and patient were then
asked to evaluate the ED using the validated EHS to
describe the current state of penile rigidity (before or
without treatment).15,16 Maintenance of erection
was evaluated by the question ‘How often are you
able to maintain your erection until the end of
sexual intercourse?’, which was based on a question
from the validated IIEF.17 Additional questions
evaluated the duration and causes of ED (aetiology,
presence of risk factors, sport activity, physician’s
request of additional exams, referral to a specialist).
Subsequently, oral treatment was discussed (pa-
tients’ reactions to PDE5i treatment and treatment
expectations in terms of penile rigidity, onset of
action, maintenance of erection, natural-feeling
sexual intercourse and duration of action). Finally,
the utility of the questionnaire to facilitate dialogue
between physicians and patients on ED and erection
hardness was recorded. Data collected using the
case report forms were scanned (Lambda-Plus SA)
for statistical analysis by an independent expert
(Professor A Albert).
Statistical methods
Results were expressed as means±s.d. for quantita-
tive variables and scores, while frequencies and
percentages were used for categorical variables.
Mean values were compared by one-way analysis
of variance or Student’s t-test, and proportions by w2-
test for contingency tables. Non-parametric Kruskal–
Wallis and Wilcoxon’s tests were used for comparing
samples from different groups when normality
assumptions could not be fulfilled. Correlation
coefficients (classical or non-parametric Spearman)
were calculated for measuring the association
between two quantitative variables. Results were
considered to be significant at the 5% critical level
(Po0.05). Data analysis was carried out using SAS




A total of 382 physicians participated in this study,
of whom 341 (89%) were GPs and 41 (11%) were
urologists. Mean ages of the physicians were
50.0±8.9 years and 45.7±10.2 in general and
urological practice, respectively. While GPs were
evenly distributed among urban, semi-urban and
rural areas, urologists practiced mainly in an urban
environment.
Additional examinations were considered more
often by urologists than by GPs (32 vs 20%). A
minority of GPs (14%) encouraged their patients to
consult a urologist, and only 4% of physicians
advised their patients to see a psychologist or
sexologist for their erection problems.
Characteristics of patients with ED
Of 2053 patients screened, 1492 for whom a
complete dataset was available were included in
the final analysis. Of these, 1338 patients (90%)
consulted a GP and 154 (10%) consulted a urologist.
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Characteristics of the 1492 patients are summarized
in Table 1. Patients had a mean age of 56±11 years
and were equally distributed across the Flemish
(55%) and French (45%) regions of Belgium. Most
patients (89%) were in a stable relationship of more
than 1 year.
Of men with ED, 59% had an EHS score of 1
(penis is larger, but not hard) or 2 (penis is hard, but
not hard enough for penetration), and only 3.4%
were able to achieve an erection score of 4
(Figure 1a). Most patients (83.1%) had trouble
maintaining erections until the end of sexual
intercourse (Figure 1b). A statistically highly sig-
nificant correlation between the grade of rigidity
and maintenance of erection was found (Po0.0001)
(Figure 2). Of patients with a score 4 erection, 68%
could maintain the rigidity until the end of sexual
intercourse always or most of the time. For score 3
erections, the corresponding percentage was only
25%. Patients practising sport for a mean
of 2.6±1.7 h per week showed higher grades of
erection rigidity (odds ratio (OR), 0.75; Po0.05) and
less severe ED (OR, 0.71; Po 0.05).
Erectile dysfunction had been discussed with the
physician previously by 43% of patients, but 74% of
patients were receiving no treatment for ED at the
time of the study. Most patients (85%) had at least
one known risk factor for ED, and 25% of men
reported an ED duration of more than 3 years. The
presence of the different risk factors, and the odds
that the physician initiated the discussion on ED
rather than the patient or partner, are presented in
Table 2. Overall, 41% of the patients had three or
more risk factors and the number of risk factors
increased with age (Po0.0001). Only 18% of
physicians initiated the conversation on ED, with
GPs more likely to start communication about ED
with patients presenting with at least one risk factor,
those with diabetes or hypertension, or those
receiving medication that could lead to ED (all
Po0.05). The presence of depression, hyperlipidae-
mia or whether a patient smokes did not increase the
Table 1 Characteristics of the patients presenting with ED
Variable GP (N¼1338) Urologist (N¼ 154) Total (N¼ 1492) P-value
Age (years), mean±s.d. 56.6±10.9 55.3±11.6 56±11 0.19
Region (%) 0.70
North 45 47 45
South 55 53 55
Stable relationship with partner (%) 89 92 89 0.26
Reason for consultation, n (%)
ED 553 (41) 110 (72) 663 (45) o0.0001
Other 764 (57) 39 (25) 803 (54)
Both 16 (1) 4 (3) 20 (1)
First discussion of ED (%) 54 78 57 o0.0001
Presence of partner during consultation (%) 20 28 21 0.021
Duration of troubles, n (%) 0.58
o1 year 441 (34) 56 (37) 497 (34)
1–3 years 525 (41) 62 (41) 587 (41)
43 years 330 (25) 33 (22) 363 (25)
Score of erection hardness, n (%) 0.0008
1 203 (15) 34 (22) 237 (16)
2 593 (45) 43 (28) 636 (43)
3 491 (37) 68 (44) 559 (38)
4 42 (3) 8 (5) 50 (3)
Severity of EDa, n (%) 0.36
Mild 173 (13) 26 (17) 199 (14)
Moderate 642 (50) 68 (46) 710 (49)
Severe 471 (37) 55 (37) 526 (37)
Aetiology of EDa, n (%) 0.10
Organic 400 (31) 55 (39) 455 (32)
Psychogenic 350 (27) 29 (20) 379 (27)
Mixed 526 (41) 58 (41) 584 (41)
Current ED treatment (%) 26 29 27 0.47
Abbreviations: ED, erectile dysfunction; GP, general practitioner.
a
According to the physician.
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chance of a GP initiating discussion about ED. In
urological practice, surgery for prostate cancer
increased sevenfold the chance of the physician
initiating the discussion (Po0.05).
In urological consultations, partners were signifi-
cantly more likely to be present than those in
general practice. Patients accompanied by their
partner were generally older (Po0.05), had more
severe ED (Po0.0001) and discussed ED for the first
time (Po0.01). When the partner was present, the
latter initiated the discussion on ED as often as the
patient in general practice (41 vs 42%), while it
was primarily the patient in urological practice
(17 vs 73%).
Patient expectations for treatment with a PDE5
inhibitor
Figure 3 presents the initial reaction of patients to
discussion of PDE5i treatment. In total, 25% of
patients rapidly confirmed their interest, while 34%
were already informed about these agents and 21%
requested treatment themselves. Concerns about
safety were raised only by 7.5% of patients, who
were generally older.
The order of preference for patients’ expectations
of PDE5i treatment is presented in Figure 4. Erection
hardness and maintenance of erection were rated as
very important by 88.7 and 91.6% of patients,
respectively. Natural-feeling sexual intercourse was
rated as very important by 63.1% of the patients,
while fast onset and long duration of action of
treatment were considered to be important by only
30.0 and 16.7% of patients, respectively. When
asked to choose between two propositions about
their expectations of ED, improvement of erection
hardness was clearly preferred over fast onset by
92.4% of patients and over long duration of action
by 93.6% of patients. Interestingly, 66 and 71% of
the patients in general and urological practice made
spontaneous reference to the importance of erection
hardness or their wish to obtain a harder erection,
especially when ED was the primary reason for
consultation (Po0.0001 for general practice and
Po0.05 for urological practice).
Utility of questionnaire in discussion of ED and
erection hardness
Most GPs (81%) and their patients (83%) considered
the questionnaire including the EHS to be a useful
tool for initiating communication on ED. In addi-
tion, for 87 and 85% of GPs and their patients,
respectively, the questionnaire was helpful in
prompting discussion of the importance of the
penile rigidity. A total of 41% of men who consulted
their GP did so because of ED (Table 1).
In urological practice, where 72% of men were
consulting for a diagnosis of ED, the questionnaire
facilitated the discussion about ED for 68% of the
patients but only 46% of urologists. Regarding the
discussion of the importance of penile rigidity, 72%
of patients considered the questionnaire to be
helpful compared with 48% of urologists.
Discussion
SCORED was designed to characterize patients with
ED and to evaluate a questionnaire as a tool for
stimulating and facilitating communication on ED
and erection hardness. Importantly, satisfaction
with erection hardness correlates with sexual satis-
faction and improvements in emotional well being,
and overall health and quality of life for patients and
Figure 1 (a) Erection Hardness Score (EHS) and (b) maintenance
of rigidity for patients with erectile dysfunction (ED).
Figure 2 Association between Erection Hardness Score (EHS)
and maintenance of erection until the end of sexual intercourse
(Po0.0001 for all comparisons).
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their partners,11,14,18–20 and thus evaluation of this
parameter is a key part of assessing ED. One way of
measuring erection hardness is through use of the
EHS,15,16 and the present study was the first
epidemiological study of ED to use this instrument.
Of men included in the analysis, 41% had score 3
or 4 erections, but most men reported an inability to
maintain erection until the end of intercourse most
of the time. A surprisingly large number of men with
score 3 erections (38%) talked about ED with their
physician, and maintenance of erection seems to be
the reason why most men with score 3 are
considered to have moderate instead of mild ED
(only 14% of men were considered to have mild ED).
Therefore, these patients were actually complaining
about maintenance problems due to insufficient
rigidity. There is also a significant correlation
between rigidity and maintenance of erections,
which is to be expected, given the importance of
passive venous compression in tumescence phase to
provide a good, stable erection.21
Duration of ED was o3 years in three-quarters of
patients, showing a positive trend compared with a
previous study in which only 66% of patients
reported a duration of o3 years.22 Results of the
present study show however that two-thirds of men
waited for 41 year before addressing issues of ED
with their physician, with the associated detrimen-
tal effects on their sexual relationships.23 Further-
more, most men in the study were in a stable
relationship, with the partner present in one-fifth of
consultations and often responsible for initiating the
discussion on ED. Taken together, these results
suggest that there is still some reluctance of men to
discuss ED with their physician, and that it is
often the partner who seeks counselling. In addition,
three-quarters of the patients in the study were not
receiving treatment for ED at the time of the study,
suggesting that, in contrast to what is often believed,
many physicians do not immediately prescribe
PDE5i treatment when discussing ED with a patient.
Although ED has been identified as an indepen-
dent marker of cardiovascular risk, and the majority






General practitioner (N¼1338) Urologist (N¼154)
OR 95% CI OR 95% CI
At least one risk factor 1.64* 1.06–1.54 1.37 0.28–6.59
Additional risk factor 1.18* 1.08–1.28 0.90 0.60–1.34
Diabetes 271 (19) 2.00* 1.45–2.75 1.03 0.21–5.02
Vascular intervention 93 (6.4) 1.15 0.67–1.98 NAa
Medication 385 (27) 1.46* 1.09–1.96 NAa
Surgery for hyperplasia 65 (4.5) 0.99 0.50–1.93 4.30 0.77–24.1
Surgery for prostate cancer 48 (3.3) 1.23 0.55–2.74 7.00* 1.77–27.8
Hypertension 617 (42) 1.74* 1.32–2.29 1.30 0.39–4.30
Smoking 576 (40) 1.29 0.98–1.29 1.26 0.53–1.88
Hyperlipidaemia 482 (33) 1.00 0.75–1.35 NAa
Alcohol 416 (29) 1.09 0.81–1.46 0.44 0.05–3.60
Depression 252 (17) 0.97 0.68–1.38 NAa
Angina/chest pains 40 (2.8) 1.29 0.60–2.76 NAa
Abbreviations: CI, confidence interval; NA, not available; OR, odds ratio.
a
The physician never initiated the discussion when the patient presented with this risk factor.
*Po0.05.
Figure 3 Initial reaction of the patients to proposition of
treatment with a phosphodiesterase type 5 (PDE5) inhibitor.
Figure 4 Order of preference given by the patients to their
expectations of phosphodiesterase type 5 (PDE5) inhibitor treatment.
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of the patients in this study presented with one or
more risk factors, physicians initiated communica-
tion about ED only in a limited number of cases, and
only a minority of physicians requested additional
examinations to characterize ED. Moreover, whether
a patient smoked, was depressed or had hyperlipi-
daemia did not increase the chance of a GP initiating
discussion about ED. More effort should therefore be
made to stimulate physicians to ask men about
sexual dysfunction when consulted by patients with
one or more co-morbidities. Conversely, screening
for other cardiovascular risk factors should be
considered when a patient presents with ED.
When the subject of PDE5i treatment was raised,
most patients rapidly confirmed their interest,
already seemed informed or even requested such
treatment themselves. Patients cited rigidity of
erections as the most important treatment expecta-
tion, while fast onset and long duration of action
were considered least important. It was also clear
that patients want to talk about erection hardness—
66% in general practice and 71% in urological
practice made spontaneous reference to the impor-
tance of penile rigidity or their wish to obtain harder
erections. It appears therefore that patients are less
embarrassed as compared to physicians regarding
erection hardness during discussions about ED
and its treatment. Only a minority of patients worry
about safety of PDE5i treatment, and this appears to
have decreased substantially from 60% of patients
in a previous study22 to 7.5% in the present study.
Regarding use of a structured questionnaire
including EHS, patients and GPs were comfortable
with the questionnaire, with most GPs and most of
their patients considering it helpful in discussing
ED. Moreover, over half of patients discussed ED
despite visiting their GP for other reasons. Use of the
questionnaire may also facilitate appropriate treat-
ment, as almost three-quarters of patients were
receiving no treatment for ED at the time of the
study, despite the fact that ED had been discussed
with the physician previously by over 40% of
patients, and over 40% presented with at least three
risk factors for ED. Of patients visiting a urologist,
up to 72% considered the questionnaire to be
helpful, but less than half of the urologists shared
their opinion. These results show that the ques-
tionnaire is most useful for GPs, who are less used to
discussing ED with their patients as compared to
urologists. In addition, urologists see more men
because of ED and these men are more likely to
initiate a discussion with such a physician, who is
more used to hearing about ED. Overall, the results
are consistent with a previous study of 1191
physicians, in which a short questionnaire was
found to be highly acceptable to patients, prompting
54% of discussions of sexual health.24
One important strength of SCORED is the large
patient cohort. Furthermore, physicians were
not asked to find new patients, but to use the
questionnaire only when they felt it was appropriate
to talk about ED or when a patient initiated
discussion themselves. Thus, the inclusion criteria
for the analysis were very broad. In addition,
patients’ expectations were discussed and priori-
tized in four different ways (order of preference;
classification according to very important, neutral,
not important; binary choice between propositions;
spontaneous reference to rigidity by the patient) to
avoid biasing answers by the way questions were
asked. Notably, there was a high level of consistency
between the results of the four approaches. Bias may
also have been avoided by the fact that the
population consisted mostly of untreated men,
reducing expectations based on previous treatment
experiences. One possible limitation of the study is
that only men who attended a physician (GP or
urologist) were included, which could limit extrapola-
tion of the results to the overall male population.
In conclusion, results of the SCORED study show
that GPs initiate discussion about ED only in a
minority of cases, even when patients have multiple
risk factors. In addition, a large number of patients
with not fully rigid erections talk about ED with
their physician, thus demonstrating the importance
of the treatment goal to achieve completely hard
erections and, consequently, sufficient maintenance.
There is a significant correlation between rigidity
and maintenance of erections, and rigidity of
erections is also the most important expectation for
PDE5i treatment, while fast onset and long duration
of action are considered least important. Only a
minority of patients worry about safety of PDE5i’s.
This should encourage the physician to avoid
hesitating when initiating treatment, even at the
first consultation. Overall, the results show that a
questionnaire including EHS is useful to facilitate
discussion about ED in general practice.
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